Literature DB >> 21880793

Iron modifies plasma FGF23 differently in autosomal dominant hypophosphatemic rickets and healthy humans.

Erik A Imel1, Munro Peacock, Amie K Gray, Leah R Padgett, Siu L Hui, Michael J Econs.   

Abstract

CONTEXT: In autosomal dominant hypophosphatemic rickets (ADHR), fibroblast growth factor 23 (FGF23) resists cleavage, causing increased plasma FGF23 levels. The clinical phenotype includes variable onset during childhood or adulthood and waxing/waning of hypophosphatemia. Delayed onset after puberty in females suggests iron status may be important.
OBJECTIVE: Studies were performed to test the hypothesis that plasma C-terminal and intact FGF23 concentrations are related to serum iron concentrations in ADHR. DESIGN AND
SETTING: Cross-sectional and longitudinal studies of ADHR and a cross-sectional study in healthy subjects were conducted at an academic medical center. PARTICIPANTS: Participants included 37 subjects with ADHR mutations from four kindreds and 158 healthy adult controls. MAIN OUTCOME MEASURE: The relationships of serum iron concentrations with plasma C-terminal and intact FGF23 concentrations were evaluated.
RESULTS: Serum phosphate and 1,25-dihydroxyvitamin D correlated negatively with C-terminal FGF23 and intact FGF23 in ADHR but not in controls. Serum iron was negatively correlated to both C-terminal FGF23 (r = -0.386; P < 0.05) and intact FGF23 (r = -0.602; P < 0.0001) in ADHR. However, control subjects also demonstrated a negative relationship of serum iron with C-terminal FGF23 (r = -0.276; P < 0.001) but no relationship with intact FGF23. Longitudinally in ADHR subjects, C-terminal FGF23 and intact FGF23 concentrations changed negatively with iron concentrations (P < 0.001 and P = 0.055, respectively), serum phosphate changed negatively with C-terminal FGF23 and intact FGF23 (P < 0.001), and there was a positive relationship between serum iron and phosphate (P < 0.001).
CONCLUSIONS: Low serum iron is associated with elevated FGF23 in ADHR. However, in controls, low serum iron was also associated with elevated C-terminal FGF23, but not intact FGF23, suggesting cleavage maintains homeostasis despite increased FGF23 expression.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21880793      PMCID: PMC3205884          DOI: 10.1210/jc.2011-1239

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  26 in total

1.  FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis.

Authors:  Takashi Shimada; Hisashi Hasegawa; Yuji Yamazaki; Takanori Muto; Rieko Hino; Yasuhiro Takeuchi; Toshiro Fujita; Kazuhiko Nakahara; Seiji Fukumoto; Takeyoshi Yamashita
Journal:  J Bone Miner Res       Date:  2003-12-29       Impact factor: 6.741

2.  Increased circulatory level of biologically active full-length FGF-23 in patients with hypophosphatemic rickets/osteomalacia.

Authors:  Yuji Yamazaki; Ryo Okazaki; Minako Shibata; Yukihiro Hasegawa; Kohei Satoh; Toshihiro Tajima; Yasuhiro Takeuchi; Toshiro Fujita; Kazuhiko Nakahara; Takeyoshi Yamashita; Seiji Fukumoto
Journal:  J Clin Endocrinol Metab       Date:  2002-11       Impact factor: 5.958

3.  Osteoporosis in hemochromatosis: iron excess, gonadal deficiency, or other factors?

Authors:  T Diamond; D Stiel; S Posen
Journal:  Ann Intern Med       Date:  1989-03-15       Impact factor: 25.391

4.  Autosomal-dominant hypophosphatemic rickets (ADHR) mutations stabilize FGF-23.

Authors:  K E White; G Carn; B Lorenz-Depiereux; A Benet-Pages; T M Strom; M J Econs
Journal:  Kidney Int       Date:  2001-12       Impact factor: 10.612

5.  Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23.

Authors: 
Journal:  Nat Genet       Date:  2000-11       Impact factor: 38.330

6.  Autosomal dominant hypophosphatemic rickets/osteomalacia: clinical characterization of a novel renal phosphate-wasting disorder.

Authors:  M J Econs; P T McEnery
Journal:  J Clin Endocrinol Metab       Date:  1997-02       Impact factor: 5.958

7.  Genome-wide association study of bone mineral density in premenopausal European-American women and replication in African-American women.

Authors:  Daniel L Koller; Shoji Ichikawa; Dongbing Lai; Leah R Padgett; Kimberly F Doheny; Elizabeth Pugh; Justin Paschall; Siu L Hui; Howard J Edenberg; Xiaoling Xuei; Munro Peacock; Michael J Econs; Tatiana Foroud
Journal:  J Clin Endocrinol Metab       Date:  2010-02-17       Impact factor: 5.958

8.  Mutant FGF-23 responsible for autosomal dominant hypophosphatemic rickets is resistant to proteolytic cleavage and causes hypophosphatemia in vivo.

Authors:  Takashi Shimada; Takanori Muto; Itaru Urakawa; Takashi Yoneya; Yuji Yamazaki; Katsuya Okawa; Yasuhiro Takeuchi; Toshiro Fujita; Seiji Fukumoto; Takeyoshi Yamashita
Journal:  Endocrinology       Date:  2002-08       Impact factor: 4.736

9.  FGF23 is processed by proprotein convertases but not by PHEX.

Authors:  Anna Benet-Pagès; Bettina Lorenz-Depiereux; Hans Zischka; Kenneth E White; Michael J Econs; Tim M Strom
Journal:  Bone       Date:  2004-08       Impact factor: 4.398

10.  Transgenic mice expressing fibroblast growth factor 23 under the control of the alpha1(I) collagen promoter exhibit growth retardation, osteomalacia, and disturbed phosphate homeostasis.

Authors:  Tobias Larsson; Richard Marsell; Ernestina Schipani; Claes Ohlsson; Osten Ljunggren; Harriet S Tenenhouse; Harald Jüppner; Kenneth B Jonsson
Journal:  Endocrinology       Date:  2004-02-26       Impact factor: 4.736

View more
  108 in total

1.  C-Terminal Fibroblast Growth Factor 23, Iron Deficiency, and Mortality in Renal Transplant Recipients.

Authors:  Michele F Eisenga; Marco van Londen; David E Leaf; Ilja M Nolte; Gerjan Navis; Stephan J L Bakker; Martin H de Borst; Carlo A J M Gaillard
Journal:  J Am Soc Nephrol       Date:  2017-08-03       Impact factor: 10.121

Review 2.  The expanding family of hypophosphatemic syndromes.

Authors:  Thomas O Carpenter
Journal:  J Bone Miner Metab       Date:  2011-12-14       Impact factor: 2.626

3.  Does bone structure accurately reflect serum FGF23 levels in patients with chronic kidney disease?

Authors:  Keitaro Yokoyama; Akio Nakashima; Yukio Maruyama; Ichiro Ohkido; Takashi Yokoo
Journal:  Kidney Int       Date:  2015-09       Impact factor: 10.612

Review 4.  Experience with intravenous ferric carboxymaltose in patients with iron deficiency anemia.

Authors:  David B Bregman; Lawrence T Goodnough
Journal:  Ther Adv Hematol       Date:  2014-04

Review 5.  FGF23 and Phosphate Wasting Disorders.

Authors:  Xianglan Huang; Yan Jiang; Weibo Xia
Journal:  Bone Res       Date:  2013-06-28       Impact factor: 13.567

6.  Iron deficiency drives an autosomal dominant hypophosphatemic rickets (ADHR) phenotype in fibroblast growth factor-23 (Fgf23) knock-in mice.

Authors:  Emily G Farrow; Xijie Yu; Lelia J Summers; Siobhan I Davis; James C Fleet; Matthew R Allen; Alexander G Robling; Keith R Stayrook; Victoria Jideonwo; Martin J Magers; Holly J Garringer; Ruben Vidal; Rebecca J Chan; Charles B Goodwin; Siu L Hui; Munro Peacock; Kenneth E White
Journal:  Proc Natl Acad Sci U S A       Date:  2011-10-17       Impact factor: 11.205

7.  Sustained Klotho delivery reduces serum phosphate in a model of diabetic nephropathy.

Authors:  Julia M Hum; Linda M O'Bryan; Arun K Tatiparthi; Erica L Clinkenbeard; Pu Ni; Martin S Cramer; Manoj Bhaskaran; Robert L Johnson; Jonathan M Wilson; Rosamund C Smith; Kenneth E White
Journal:  J Appl Physiol (1985)       Date:  2019-01-03

8.  Iron and fibroblast growth factor 23 in X-linked hypophosphatemia.

Authors:  Erik A Imel; Amie K Gray; Leah R Padgett; Michael J Econs
Journal:  Bone       Date:  2013-12-08       Impact factor: 4.398

Review 9.  Fibroblast growth factor 23 and acute kidney injury.

Authors:  Javier A Neyra; Orson W Moe; Ming Chang Hu
Journal:  Pediatr Nephrol       Date:  2014-12-06       Impact factor: 3.714

Review 10.  Non-renal-Related Mechanisms of FGF23 Pathophysiology.

Authors:  Mark R Hanudel; Marciana Laster; Isidro B Salusky
Journal:  Curr Osteoporos Rep       Date:  2018-12       Impact factor: 5.096

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.